• Prophylaxis of stroke and thromboembolism in nonvavular atrial fibrillation:
    • PO 150mg BD
    • If CrCl at 15-30ml/min: 75mg BD
  • Treatment of DVT/PE:
    • PO 150mg BD
    • Initiate immediately after unfractionated heparin infusion discontinuation or if transitioning from LMWH, give 0-2 hrs before next LMWH dose would have been administered
    • For patients initially treated with parenteral anticoagulant for 5-10 days
  • Prophylaxis of recurrent DVT/PE:
    • PO 150mg BD
  • Prophylaxis of DVT/PE in hip replacement :
    • PO 110mg 1-4 hr after surgery and after hemostasis has been achieved on first day, then 220 mg taken OD *28-35 days
    • If dabigatran is not started on the day of surgery, after hemostasis has been achieved treatment started with 220mg OD
  • Tablet:
    • 75mg
    • 150mg
    • 110mg
  • To convert from parenteral anticoagulants, discontinue parenteral anticoagulant and start dabigatran 0-2 hours before next scheduled dose
  • Consider holding treatment 1-2 days before surgery or invasive procedure if CrCl >50 or 3-5 days if CrCl <50

Anticoagulant

It direct inhibits thrombin thereby prevents thrombus formation

  • Bleeding
  • Dyspepsia
  • Gastritis
  • Vomiting (peds patients)
  • Nausea (peds patients)
  • Diarrhea (peds patients)
  • Abdominal pain (peds patients)
  • Hypersensitivity to class/components
  • Active major bleeding
  • Pregnancy
  • CrCl <15 (thromboembolism prevention or stroke prevention use)
  • eGFR <50 (peds patients)
  • Mechanical heart valve
  • Antiphospholipid syndrome
  • Defibrotide
  • Mifepristone

                          Drug Status

Availability Prescription only
Pregnancy Category C
Breastfeeding Not recommended
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Pradaxa 75mg Capsule 30’s, 60’s Boehringer Ingelheim Surgipharm Ltd
Pradaxa 110mg Capsule 30’s, 60’s Boehringer Ingelheim Surgipharm Ltd
Pradaxa 150mg Capsule 60’s Boehringer Ingelheim Surgipharm Ltd